Trial Profile

A Phase III, Randomized Trial of BC 819 in Patients with Bladder Cancer who Failed Initial Treatment with BCG

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Sep 2018 According to a Anchiano Therapeutics website, Codex study and Leo study will support an application for marketing approval in the US and other countries of inodiftagene vixteplasmid (BC 819) for use in the treatment of bladder cancer.
07 Sep 2018 According to a Anchiano Therapeutics website, the company is planning to launch this study in early 2019. (link: https://www.anchiano.com/lead-program/future-development-plan/ )
07 Sep 2018 Planned number of patients changed from 470 to 495, according to a Anchiano Therapeutics website.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com